The new tool empowers lower skilled healthcare workers to quickly and accurately calculate gestational age, without needing image interpretation or...
COLD SPRING HARBOR, N.Y., Oct. 2, 2025 /PRNewswire/ -- Branching isn't just for trees. This biological process occurs in animal development,...
The State of Female Reproductive Health Knowledge in the US 82% of U.S. women are concerned about encountering medical misinformation...
European-inspired social club for parents-to-be blends expert-led education with lasting friendships. Registration now open for November 2025 cohorts. The journey...
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every...
Recognition in breast augmentation and liposuction highlights Dr. Doherty's expertise in two of the most requested cosmetic procedures, underscoring his...
Engagement Will Expand Daré’s Engagement in Advancing Women’s Health Innovation and Provide Insights into One of the Most Significant Unmet...
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults...
WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- As the medication experts, APhA affirms there has been no new evidence in two...
THOUSAND OAKS, CA / ACCESS Newswire / September 22, 2025 / After months of anticipation, The Midwife & More proudly...
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with...
Annual event recognizes top digital health solutions and connects international thought leaders OLATHE, Kan., Sept. 19, 2025 /PRNewswire/ -- Garmin...
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies,...
Rethink Impact leads investment round as company targets expansion to 30+ states by end of 2026 WASHINGTON, DC / ACCESS...
Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for...
Strategic agreement leverages Garmin biometric data for digital health research OLATHE, Kan., Sept. 17, 2025 /PRNewswire/ -- Garmin (NYSE: GRMN) today...
Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1) Planning adaptive Phase...
Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing...
Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing...
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation...